FDA Approves First Drug for Idiopathic Hypersomnia FDA Approves First Drug for Idiopathic Hypersomnia
Xywav, an oral solution of calcium, magnesium, potassium, and sodium oxybates, was approved last year for treating cataplexy or excessive daytime sleepiness in patients with narcolepsy.FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
More News: Brain | Calcium | Hypersomnia | Idiopathic Hypersomnia | Magnesium | Narcolepsy | Neurology | Neurosurgery | Potassium | Sleep Medicine | Sodium